Interestingly, pan-cancer cohort analysis indicated that KRAS-mutant patients with high ATR expression (389/907, 42.9%) had a significantly lower OS rate than patients with low ATR expression (Supplementary Fig. 1b). This evidence concerns the gene KRAS and cancer.